[AZN] Astrazeneca PLC

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.

 

Price: 27.31 Change: 0.14 (0.5%)
Ext. hours: Change: 0 (0%)

chart AZN

Refresh chart

Strongest Trends Summary For AZN

AZN is in the long-term up 39% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention

Fundamental Ratios
Shares Outstanding EPS3.52 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y156.85% Sales Growth - 4 Quarters Sales Growth - Q/Q P/E9.81
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-2.39 B Cash From Investing Activities-1.23 B Cash From Operating Activities1.01 B Gross Profit5.3 B
Net Profit697 M Operating Profit923 M Total Assets55.17 B Total Current Assets13.81 B
Total Current Liabilities16.15 B Total Debt11.01 B Total Liabilities36.89 B Total Revenue6.31 B
Technical Data
High 52 week43.02 Low 52 week32.97 Last close37.78 Last change-0.05%
RSI45.85 Average true range0.63 Beta0.64 Volume2.88 M
Simple moving average 20 days-0.78% Simple moving average 50 days-5.71% Simple moving average 200 days-2.2%
Performance Data
Performance Week0.35% Performance Month-2.55% Performance Quart-5.56% Performance Half0.08%
Performance Year11.61% Performance Year-to-date-5.24% Volatility daily1.11% Volatility weekly2.47%
Volatility monthly5.07% Volatility yearly17.55% Relative Volume389.21% Average Volume5.47 M
New High New Low

News

2020-05-31 17:32:56 | Bristol-Myers Deserves Better Than a Single-Digit Multiple

2020-05-29 16:14:49 | AstraZeneca Scored A 'Home Run' With Its Cancer Drug — And Shares Popped

2020-05-29 12:19:00 | AstraZeneca's Blockbuster Lung Cancer Drug Has a Huge Sales Boost Ahead

2020-05-29 10:29:00 | AstraZeneca Reports Progress With Lung Cancer Drug

2020-05-29 09:37:01 | Pharma Stock Roundup: MRK, RHHBY Give Coronavirus Updates,SNY to Sell Stake in REGN

2020-05-29 09:13:00 | AstraZeneca Stock Jumps on Strong Cancer Drug Data

2020-05-29 08:38:00 | The Dow Is Edging Down. Salesforce.com Falls as AstraZeneca Rises.

2020-05-29 08:01:00 | IMFINZI® durvalumab Showed a Sustained Overall Survival Benefit in 1st-Line Extensive-Stage Small Cell Lung Cancer in the Phase III CASPIAN Trial

2020-05-29 08:01:00 | IMFINZI plus tremelimumab Demonstrated Promising Clinical Activity and Tolerability in Patients With Advanced Liver Cancer

2020-05-29 08:00:00 | ENHERTU fam-trastuzumab deruxtecan-nxki Demonstrated Meaningful Clinical Activity in Patients With HER2-mutant Non-small Cell Lung Cancer in Interim Analysis of Phase II DESTINY-Lung01 Trial

2020-05-29 08:00:00 | ENHERTU fam-trastuzumab deruxtecan-nxki Achieved a Tumor Response Rate of 45.3% in Patients With HER2-Positive Metastatic Colorectal Cancer in Phase II DESTINY-CRC01

2020-05-29 08:00:00 | ENHERTU fam-trastuzumab deruxtecan-nxki Significantly Improved Tumor Response Rate and Overall Survival in HER2-positive Metastatic Gastric Cancer in Phase II DESTINY-Gastric01 Trial

2020-05-29 02:00:10 | Chi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations

2020-05-28 21:05:03 | A selection of the FT’s biggest stories and best reads every Friday

2020-05-28 17:10:47 | AstraZeneca Unveils Data Behind New Win For Blockbuster Drug

2020-05-28 17:00:00 | TAGRISSO Demonstrated Unprecedented Patient Benefit in the Adjuvant Treatment of EGFR-Mutated Lung Cancer

2020-05-28 11:01:20 | AstraZeneca says it may consider exposing vaccine trial participants to virus

2020-05-28 10:56:18 | Pfizer ties up with glass maker Corning for vial supply

2020-05-28 00:00:32 | The lessons and consequences of a failed megadeal

2020-05-27 12:31:04 | Biotech ETFs Soaring on COVID-19 Vaccine Progress

2020-05-27 12:07:26 | Trump’s ‘Operation Warp Speed’: No way it happens, says infectious disease expert

2020-05-27 00:00:44 | Drug wars: how AstraZeneca overtook GSK in UK pharma

2020-05-26 11:53:20 | Novavax expects COVID-19 vaccine trial results in July

2020-05-26 10:53:02 | The Zacks Analyst Blog Highlights: Bristol-Myers, Roche, AstraZeneca, Merck and Johnson & Johnson

2020-05-26 10:52:02 | The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline

2020-05-26 09:59:42 | Novavax and Merck Fuel COVID-19 Vaccine Hopes

2020-05-26 08:00:12 | Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up

2020-05-25 02:35:48 | How Much is AstraZeneca PLC's LON:AZN CEO Getting Paid?

2020-05-24 13:39:00 | Oxford Professor Lowers Coronavirus Vaccine's Odds of Meeting September Deadline

2020-05-24 08:21:59 | An 'unprecedented' effort to find a coronavirus vaccine has over 100 horses in the race

2020-05-23 17:22:14 | Project leader: Oxford's COVID-19 vaccine trial has 50% chance of success - Telegraph

2020-05-22 15:49:00 | Chinese Covid-19 Vaccine Trial Results Are a Good Sign for J&J and AstraZeneca’s Efforts

2020-05-22 15:44:38 | Novavax Hopes to Reverse Past Setbacks With Covid-19 Vaccine

2020-05-22 11:56:25 | INSIGHT-How one Indian company could be world's door to a COVID-19 vaccine

2020-05-22 10:31:00 | A Covid-19 Vaccine Could Be Ready Late This Year, Bernstein Analyst Says

2020-05-22 09:22:37 | The race for a coronavirus treatment is fanning fears of 'vaccine nationalism'

2020-05-22 07:29:00 | Goldman Borrows U.K. Slogan Against Virus to Apply to British Stocks — ‘Stay Alert, Keep Distance’

2020-05-22 05:58:07 | Human trials of British coronavirus vaccine to reach 10,000

2020-05-22 05:37:09 | Pharma Stock Roundup: FDA Ok's Cancer Drugs for New Use, JNJ Stops US Baby Powder Sales

2020-05-22 02:51:06 | Coronavirus Vaccine Race Pushes Up Pharma Giants' Production

2020-05-21 19:04:50 | U.S. Cases Rise 1.5%; Americans Defer Medical Care: Virus Update

2020-05-21 16:49:24 | 4 Top Stock Trades for Friday: NVDA, LULU, TJX, AZN

2020-05-21 16:22:14 | The US just bought 400 million doses of a coronavirus vaccine that may never exist

2020-05-21 16:21:47 | AstraZeneca Pops On $1.2 Billion In Funding For Coronavirus Vaccine

2020-05-21 15:48:12 | Fmr. CDC Official: 'we’re not cutting any corners' on COVID-19 vaccine development

2020-05-21 15:25:18 | Coronavirus latest: Thursday, May 21

2020-05-21 14:24:29 | Clovis Oncology Needs a Savior

2020-05-21 13:48:54 | Coronavirus update: Worldwide count tops 5M as US inches toward reopening; AstraZeneca gets $1B

2020-05-21 13:32:00 | U.S. Seals Deal with AstraZeneca for 300 Million Doses of Potential Coronavirus Vaccine

2020-05-21 12:17:00 | U.S. gives AstraZeneca $1.2 billion to fund Oxford University coronavirus vaccine — America would get 300 million doses beginning in October